MarketPulse

INO-3107

13 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Inovio Investors Face April 7 Deadline in Securities Class Action Over Alleged Misstatements

Rosen Law Firm alerts $INO investors of April 7, 2026 deadline to join class action over alleged false statements regarding manufacturing and regulatory prospects.
INOsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Pomerantz Files Securities Fraud Suit Against $INO Over FDA Approval Misstatements

Pomerantz LLP sues Inovio Pharmaceuticals for alleged securities fraud over FDA approval misstatements. Stock fell 3.1% and 24.45% following manufacturing delays and accelerated approval rejection.
INOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Inovio Faces Securities Class Action Over Vaccine Device Defects, Regulatory Claims

Rosen Law Firm seeks lead plaintiffs in securities class action against Inovio Pharmaceuticals for alleged misstatements on device defects, regulatory prospects, and product timelines. Lead plaintiff deadline: April 7, 2026.
INOsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Faruqi & Faruqi, Llp

Inovio Faces Securities Class Action Over Failed FDA Approval Strategy

Inovio Pharmaceuticals faces a securities class action over allegedly false statements regarding manufacturing capabilities and regulatory prospects for INO-3107, following FDA's December 29 accelerated approval rejection.
INOstock declinesecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Inovio Faces Securities Fraud Class Action Over Manufacturing Claims and FDA Setbacks

Pomerantz Law Firm files class action against $INO for alleged securities fraud involving false manufacturing capability and FDA approval claims for INO-3107.
INOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Inovio Faces Securities Class Action Over Device Defects, Missed Regulatory Timelines

Rosen Law Firm files securities class action against Inovio Pharmaceuticals ($INO) alleging misleading statements on manufacturing deficiencies and overstated regulatory prospects. Lead plaintiff deadline April 7, 2026.
INOsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Inovio Faces Class Action Over Alleged Misstatements on Device Manufacturing and FDA Timeline

Class action lawsuit filed against Inovio Pharmaceuticals for allegedly making false statements about CELLECTRA device manufacturing and INO-3107 FDA submission timeline between October 2023 and December 2025.
INOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Inovio Faces Securities Lawsuit Over Manufacturing Claims and Regulatory Missteps

Rosen Law Firm urges $INO investors to join class action lawsuit alleging false statements about manufacturing deficiencies and regulatory prospects.
INOsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Inovio Investors Urged to File Claims Before April Deadline in Securities Litigation

Rosen Law Firm notifies Inovio investors of securities class action with April 7, 2026 lead plaintiff deadline, citing alleged false statements on manufacturing and regulatory matters.
INOinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.

Inovio Pharmaceuticals Faces Class Action Over FDA Rejection and Device Claims

Inovio Pharmaceuticals faces class action lawsuit over alleged false statements regarding manufacturing defects and regulatory prospects after FDA rejected accelerated approval, causing 24% stock decline.
INOclass action lawsuitstock decline
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Inovio Pharmaceuticals Faces Regulatory Headwinds Amid Capital Constraints

Inovio Pharmaceuticals faces FDA rejection of its lead drug candidate and mounting cash constraints, raising questions about the biotech firm's long-term viability without revenue-generating products.
INOFDA approvalbiotech
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Class Action Lawsuit Filed Against Inovio Over Alleged Misstatements on Device Manufacturing and Regulatory Plans

Class action lawsuit filed against Inovio Pharmaceuticals for allegedly making false statements about device manufacturing capabilities and regulatory timelines between October 2023 and December 2025.
INOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Rosen Law Firm Files Securities Class Action Against Inovio Pharmaceuticals

Rosen Law Firm files securities class action against Inovio Pharmaceuticals for allegedly making false statements about manufacturing deficiencies and regulatory prospects between October 2023 and December 2025.
INOsecurities fraudclass action lawsuit